Sign In
Buy KALA
$3.54
-0.0700 (-1.94%)
At Close: Jun 22, 2026
KALA BIO Announces Chief Executive Officer Transition
08:00am, Wednesday, 12'th Feb 2025
ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative
KALA BIO Announces $10,750,000 Private Placement
08:00am, Monday, 30'th Dec 2024
ARLINGTON, Mass., Dec. 30, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative
KALA BIO (KALA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
10:57am, Monday, 16'th Dec 2024
KALA BIO (KALA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a tr
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference
08:00am, Wednesday, 27'th Nov 2024
ARLINGTON, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative
KALA BIO (KALA) Moves to Strong Buy: Rationale Behind the Upgrade
01:05pm, Wednesday, 09'th Oct 2024
KALA BIO (KALA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
KALA BIO (KALA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
10:55am, Friday, 23'rd Aug 2024
KALA BIO (KALA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall
KALA BIO to Present at Jefferies Global Healthcare Conference
08:00am, Wednesday, 29'th May 2024
ARLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative t
KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 14'th May 2024
-- Patient enrollment ongoing in Phase 2b CHASE trial of KPI-012 for PCED; targeting topline data by year-end 2024 -- -- Evaluating opportunities to expand KPI-012 development into other corneal dise
Does KALA BIO (KALA) Have the Potential to Rally 152.83% as Wall Street Analysts Expect?
10:56am, Thursday, 04'th Apr 2024
The mean of analysts' price targets for KALA BIO (KALA) points to a 152.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
08:00am, Friday, 29'th Mar 2024
-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 -- -- Exploring opportunities to expand KPI-012 into additional corneal indications -- -- Cash res
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
08:00am, Monday, 26'th Feb 2024
ARLINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 19'th Jan 2024
ARLINGTON, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside
KALA BIO (KALA) Reports Q3 Loss, Misses Revenue Estimates
10:32am, Monday, 13'th Nov 2023
KALA BIO (KALA) came out with a quarterly loss of $3.41 per share versus the Zacks Consensus Estimate of a loss of $2.15. This compares to earnings of $19.25 per share a year ago.
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
08:00am, Monday, 13'th Nov 2023
-- Enrollment ongoing in CHASE Phase 2b clinical trial of KPI-012 for PCED; topline data expected in 2H 2024 -- -- As of September 30, 2023, $56.1 million in cash and cash equivalents; together with a
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Wednesday, 20'th Sep 2023
ARLINGTON, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside
